Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 12/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257599 | 0.88 | HTT (0.42) | ACACBMCOLN3KDM4EHTTNOTUM | |
| SCHEMBL19862434 | 0.85 | ACACB (0.40) | LMNAACACBC5AR1HTTTRPA1 | |
| SCHEMBL19865054 | 0.80 | ACACB (0.41) | LMNAACACBC5AR1TRPA1PTGS1 | |
| SCHEMBL12354673 | 0.79 | ACACB (0.45) | ACACBMCOLN3KDM4EHTT | |
| SCHEMBL12074844 | 0.77 | LMNA (0.52) | LMNAC5AR1MCOLN3HTTTRPA1 | |
| SCHEMBL21009647 | 0.75 | ACACB (0.48) | LMNAACACBC5AR1KDM4EHTT | |
| SCHEMBL16939771 | 0.74 | LMNA (0.44) | LMNAC5AR1KDM4EHTTTRPA1 | |
| SCHEMBL12958780 | 0.74 | NOTUM (0.64) | ACACBMCOLN3NOTUM | |
| SCHEMBL16775752 | 0.74 | NOTUM (0.64) | ACACBMCOLN3NOTUM | |
| SCHEMBL16775751 | 0.74 | NOTUM (0.64) | ACACBMCOLN3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | LMNA 3671/4885ACACB 344/4885C5AR1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.